Combining light-activated treatment with immune-blocking drugs to target pancreatic cancer
Project 3: Immune Checkpoint Inhibition Therapy Enhanced by Integrated Photodynamic Treatment and Image Guidance in Preclinical Models of Pancreatic Cancer
This project aims to make pancreatic tumors more responsive to immune-boosting drugs by using a light-activated treatment and advanced imaging to time therapy.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11195101 on NIH RePORTER |
What this research studies
Researchers use a light-activated drug (photodynamic priming) in animal models of pancreatic cancer to change the tumor environment so immune cells can enter. They combine this priming with immune checkpoint drugs (like anti-PD1) and use new hyperspectral imaging to watch multiple immune markers in living tumors. The imaging creates an "immunoscore" to pick the best moment to give immune therapy, with the goal of using lower drug doses and reducing side effects. This work is done at Massachusetts General Hospital and focuses on lab and animal studies to build a precise, image-guided approach before any human trials.
Who could benefit from this research
Good fit: People with pancreatic ductal adenocarcinoma—especially those with immune "cold" tumors who currently do not benefit from checkpoint inhibitors—would be the likely candidates for future trials.
Not a fit: Patients whose tumors already respond to existing immunotherapy or who cannot undergo localized light-based procedures may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could make resistant pancreatic tumors respond to immunotherapy and allow lower, safer doses of immune drugs.
How similar studies have performed: Some early preclinical work and limited clinical experience suggest photodynamic methods can boost immune responses, but combining imaging-guided photodynamic priming with checkpoint inhibitors in pancreatic cancer is largely novel.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Hasan, Tayyaba — Massachusetts General Hospital
- Study coordinator: Hasan, Tayyaba
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.